search this site
- home
- highlights
- sinclair at a glance
- growing our operations worldwide
- products:oral health
- products:dermatology
- chairman´s statement
- business review:operational
- business review:financial
- board of directors
- senior management
- directors´ report
- corporate governance report
- directors´ remuneration report
- independent auditors´ report
- consolidated income statement
- balance sheets
- statements of changes in shareholders´ equity
- cash flow statements
- notes to the financial statements
- corporate advisors
Products:
Dermatology
The dermatology market is diverse and covers a range of indications that affect
the skin, hair and nails.
The major skin diseases
encompassed in this
category include acne,
psoriasis and dermatitis.
Dermo-cosmetics are gaining popularity, with the anti‑ageing and anti-wrinkle market driving growth
in this area.
In 2012, the dermatological market will generate
$19.4bn with a 3% CAGR from 2006 to 2012.
Sinclair has a significant dermatology portfolio which
now comprises three product groups: prescriptions,
OTC and dermo-cosmetics (which may be promoted
to doctors, pharmacists and the public). This allows
us to develop a tailored strategy for each channel,
taking into consideration the different patient and
promotional needs.
The Sinclair product range is built on patented technologies, many of which have a long remaining
patent life.
Our key dermatology products include:
ATOPICLAIR®
(cream, lotion)
PRODUCT DESCRIPTION
Non-steroidal alternative designed
to relieve the symptoms of atopic
dermatitis (eczema), contact
(allergic, irritant) dermatitis,
and other dermatoses.
STATUS
Approved in the EU and the US.
Atopiclair® cream has also
achieved registration in Indonesia and Australia.
PROGRESS
Atopiclair® is available in 14 countries
including France, Italy, UK, US,
Germany, Spain, Austria, Portugal,
Turkey, Indonesia, Israel and
Jordan. During the year, it was
launched in five markets including
Hungary and Portugal.
SEBCLAIR®
(cream, lotion, shampoo, scalp fluid)
PRODUCT DESCRIPTION
Steroid-free range intended
for the management of
seborrheic dermatitis.
STATUS
All presentations are approved in
the EU and the cream is approved
in the US. Product registration
was granted in Australia in
September 2007.
PROGRESS
Sold in five countries.
In the US we partnered with
Dr Reddy´s Laboratories, Inc.
who are scheduled to launch
in FY2009. Dr Reddy´s is focused
on building a presence in
dermatology in the US, worth
an estimated $5.0bn annually.
DERMACHRONIC®
(cream, detergent)
PRODUCT DESCRIPTION
DermaChronic® is an emollient
non-allergenic moisturiser,
developed specifically for long
term use in remission by patients
with chronic skin conditions.
This new product is available
as a cream and a detergent
line extension.
STATUS
DermaChronic® is now approved
for sale in the EU.
PROGRESS
DermaChronic® has been
launched by Sinclair Srl in Italy.
DERMO–COSMETICS
(rinse, toothpaste, gel, spray)
PRODUCT DESCRIPTION
A range of products that help
to combat the clinical signs
of skin ageing and/or improve
the appearance of the skin.
They are formulated in cooperation
with dermatologists and contain
ingredients, whose alleviating or
therapeutic effect have been
confirmed in clinical studies.
STATUS
Sold in France, Italy, Middle East,
Portugal and Poland.
Distribution agreement in India.
PROGRESS
Distribution agreements in place
in seven countries.
Earlier in the year Sinclair acquired
products from Derma Omnium
(Bio-Taches) and Syrio Pharma
(B.lift and B.derm), which have
strengthened Sinclair´s dermocosmetic
portfolio which already
include the anti-acne range
Papulex®, the Méla´Aura range,
Fadiamone and Effadiane.
